Click here to view all research publications from the Qi laboratory.
Selected Publications
2024
Identifying regulators of aberrant stem cell and differentiation activity in colorectal cancer using a dual endogenous reporter system.
Spisak S, Chen D, Likasitwatanakul P, Doan P, Li Z, Bala P, Vizkeleti L, Tisza V, De Silva P, Giannakis M, Wolpin B, Qi J, Sethi NS. Nat Commun. 2024 Mar 12;15(1):2230. doi: 10.1038/s41467-024-46285-w.PMID: 38472198 Free PMC article.
BRD9-SMAD2/3 Orchestrates Stemness and Tumorigenesis in Pancreatic Ductal Adenocarcinoma.
Feng Y, Cai L, Pook M, Liu F, Chang CH, Mouti MA, Nibhani R, Militi S, Dunford J, Philpott M, Fan Y, Fan GC, Liu Q, Qi J, Wang C, Hong W, Morgan H, Wang M, Sadayappan S, Jegga AG, Oppermann U, Wang Y, Huang W, Jiang L, Pauklin S. Gastroenterology. 2024 Jan;166(1):139-154.
2023
A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeutics.
Lee HM, Wright WC, Pan M, Low J, Currier D, Fang J, Singh S, Nance S, Delahunty I, Kim Y, Chapple RH, Zhang Y, Liu X, Steele JA, Qi J, Pruett-Miller SM, Easton J, Chen T, Yang J, Durbin AD, Geeleher P. Nat Commun. 2023 Nov 13;14(1):7332 doi: 10.1038/s41467-023-43134-0.PMID: 37957169
Combination therapies to improve the efficacy of immunotherapy in triple-negative breast cancer.
Alečković M, Li Z, Zhou N, Qiu X, Lulseged B, Foidart P, Huang XY, Garza K, Shu S, Kesten N, Li R, Lim K, Garrido-Castro AC, Guerriero JL, Qi J, Long HW, Polyak K.Mol Cancer Ther. 2023 Sep 7. doi: 10.1158/1535-7163.MCT-23-0303. Online ahead of print.PMID: 37676980
Manipulating Tyrosine Phosphorylation by Heterobifunctional Small Molecules.
Meng X, Qi J. ACS Cent Sci. 2023 Aug 15;9(8):1512-1514. doi: 10.1021/acscentsci.3c00836. eCollection 2023 Aug 23.PMID: 37637739 Free PMC article.
Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.
de Miguel FJ, Gentile C, Feng WW, Silva SJ, Sankar A, Exposito F, Cai WL, Melnick MA, Robles-Oteiza C, Hinkley MM, Tsai JA, Hartley AV, Wei J, Wurtz A, Li F, Toki MI, Rimm DL, Homer R, Wilen CB, Xiao AZ, Qi J, Yan Q, Nguyen DX, Jänne PA, Kadoch C, Politi KA.Cancer Cell. 2023 Aug 14;41(8):1516-1534.e9. doi: 10.1016/j.ccell.2023.07.005. Epub 2023 Aug 3.PMID: 37541244 Free article.
Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1-EEF1A1 Axis.
Li M, Yang L, Chan AKN, Pokharel SP, Liu Q, Mattson N, Xu X, Chang WH, Miyashita K, Singh P, Zhang L, Li M, Wu J, Wang J, Chen B, Chan LN, Lee J, Zhang XH, Rosen ST, Müschen M, Qi J, Chen J, Hiom K, Bishop AJR, Chen CW. Adv Sci (Weinh). 2023 Jun;10(17):e2206584. doi: 10.1002/advs.202206584. Epub 2023 Apr 19.PMID: 37075745 Free PMC article.
Stepwise activities of mSWI/SNF family chromatin remodeling complexes direct T cell activation and exhaustion.
Battistello E, Hixon KA, Comstock DE, Collings CK, Chen X, Rodriguez Hernaez J, Lee S, Cervantes KS, Hinkley MM, Ntatsoulis K, Cesarano A, Hockemeyer K, Haining WN, Witkowski MT, Qi J, Tsirigos A, Perna F, Aifantis I, Kadoch C. Mol Cell. 2023 Apr 20;83(8):1216-1236.e12. doi: 10.1016/j.molcel.2023.02.026. Epub 2023 Mar 20.PMID: 36944333 Free PMC article.
Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection.
Wei J, Patil A, Collings CK, Alfajaro MM, Liang Y, Cai WL, Strine MS, Filler RB, DeWeirdt PC, Hanna RE, Menasche BL, Ökten A, Peña-Hernández MA, Klein J, McNamara A, Rosales R, McGovern BL, Luis Rodriguez M, García-Sastre A, White KM, Qin Y, Doench JG, Yan Q, Iwasaki A, Zwaka TP, Qi J, Kadoch C, Wilen CB.Nat Genet. 2023 Mar;55(3):471-483. doi: 10.1038/s41588-023-01307-z. Epub 2023 Mar 9.PMID: 36894709 Free PMC article.
BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.
Kurata K, Samur MK, Liow P, Wen K, Yamamoto L, Liu J, Morelli E, Gulla A, Tai YT, Qi J, Hideshima T, Anderson KC.Clin Cancer Res. 2023 May 1;29(9):1807-1821. doi: 10.1158/1078-0432.CCR-22-3668.PMID: 36780189 Free PMC article.
BRD9-containing non-canonical BAF complex maintains somatic cell transcriptome and acts as a barrier to human reprogramming.
Sevinç K, Sevinç GG, Cavga AD, Philpott M, Kelekçi S, Can H, Cribbs AP, Yıldız AB, Yılmaz A, Ayar ES, Arabacı DH, Dunford JE, Ata D, Sigua LH, Qi J, Oppermann U, Onder TT.Stem Cell Reports. 2022 Dec 13;17(12):2629-2642. doi: 10.1016/j.stemcr.2022.10.005. Epub 2022 Nov 3.PMID: 36332631 Free PMC article.
2022
BAF complex maintains glioma stem cells in pediatric H3K27M-glioma.
Panditharatna E, G Marques J, Wang T, Trissal MC, Liu I, Jiang L, Beck A, Groves A, Dharia NV, Li D, Hoffman SE, Kugener G, Shaw ML, Mire HM, Hack OA, Dempster JM, Lareau C, Dai L, Sigua LH, Quezada MA, Stanton AJ, Wyatt M, Kalani Z, Goodale A, Vazquez F, Piccioni F, Doench JG, Root DE, Anastas JN, Jones KL, Saur Conway A, Stopka S, Regan MS, Liang Y, Seo HS, Song K, Bashyal P, Jerome WP, Mathewson ND, Dhe-Paganon S, Suva ML, Carcaboso AM, Lavarino C, Mora J, Nguyen QD, Ligon KL, Shi Y, Agnihotri S, Agar NYR, Stegmaier K, Stiles CD, Monje M, Golub TR, Qi J#, Filbin MG# Cancer Discov. 2022 Oct 28:CD-21-1491. doi: 10.1158/2159-8290.CD-21-1491. Online ahead of print.PMID: 36305736
Aberrant Cholesterol Metabolism and Wnt/β-Catenin Signaling Coalesce via Frizzled5 in Supporting Cancer Growth.
Zheng S, Lin J, Pang Z, Zhang H, Wang Y, Ma L, Zhang H, Zhang X, Chen M, Zhang X, Zhao C, Qi J, Cao L, Wang M, He X, Sheng R. Adv Sci (Weinh). 2022 Aug 17:e2200750. doi: 10.1002/advs.202200750. Online ahead of print.
Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity.
Guan X, Cheryala N, Karim RM, Chan A, Berndt N, Qi J, Georg GI, Schönbrunn E.J Med Chem. 2022 Aug 11;65(15):10441-10458. doi: 10.1021/acs.jmedchem.2c00453. Epub 2022 Jul 22
1,4-Dihydropyridinebutyrolactone-derived ring-opened ester and amide analogs targeting BET bromodomains.
Jiang J, Zhao PL, Sigua LH, Chan A, Schönbrunn E, Qi J, Georg GI.Arch Pharm (Weinheim). 2022 Aug 8:e2200288. doi: 10.1002/ardp.202200288.
SMARCE1 deficiency generates a targetable mSWI/SNF dependency in clear cell meningioma.
St Pierre R, Collings CK, Samé Guerra DD, Widmer CJ, Bolonduro O, Mashtalir N, Sankar A, Liang Y, Bi WL, Gerkes EH, Ramesh V, Qi J, Smith MJ, Meredith DM, Kadoch C.Nat Genet. 2022 Jun;54(6):861-873. doi: 10.1038/s41588-022-01077-0. Epub 2022 Jun 9.PMID: 35681054
The FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma.
Zullow HJ, Sankar A, Ingram DR, Samé Guerra DD, D'Avino AR, Collings CK, Lazcano R, Wang WL, Liang Y, Qi J, Lazar AJ, Kadoch C.Mol Cell. 2022 Apr 4:S1097-2765(22)00257-X. doi: 10.1016/j.molcel.2022.03.019. Online ahead of print.PMID: 35390276
Exploring Methods of Targeting Histone Methyltransferases and Their Applications in Cancer Therapeutics.
Wang MY, Liow P, Guzman MIT, Qi J.ACS Chem Biol. 2022 Apr 1. doi: 10.1021/acschembio.2c00062. Online ahead of print.PMID: 35363464
BET-bromodomain and EZH2 inhibitor treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.
Zaiken MC, Flynn R, Paz KG, Rhee SY, Jin S, Mohamed FA, Saha A, Thangavelu G, Park PMC, Hemming ML, Sage PT, Sharpe AH, DuPage M, Bluestone JA, Panoskaltsis-Mortari A, Cutler CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Luznik L, Maillard I, Hill GR, MacDonald KP, Munn DH, Serody JS, Murphy WJ, Kean LS, Zhang Y, Bradner JE, Qi J#, Blazar BR#. Blood. 2022 Feb 28:blood.2021014557. doi: 10.1182/blood.2021014557. Online ahead of print.PMID: 35226736
A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia.
Ren Z, Kim A, Huang YT, Pi WC, Gong W, Yu X, Qi J, Jin J, Cai L, Roeder RG, Chen WY, Wang GG.Proc Natl Acad Sci U S A. 2022 Mar 1;119(9):e2122940119. doi: 10.1073/pnas.2122940119.PMID: 35217626
EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma.
Durbin AD*#, Wang T*, Wimalasena VK, Zimmerman MW, Li D, Dharia NV, Mariani L, Shendy NAM, Nance S, Patel AG, Shao Y, Mundada M, Maxham L, Park PMC, Sigua LH, Morita K, Saur Conway A, Robichaud AL, Perez-Atayde AR, Bikowitz MJ, Quinn TR, Wiest OG, Easton J, Schonbrunn E, Bulyk ML, Abraham BJ, Stegmaier K#, Look AT#, Qi J.# Cancer Discovery. 2021 Nov 12:candisc.0385.2021. doi: 10.1158/2159-8290.CD-21-0385. 2022, 730-751
2021 Key Publications
Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma
Ohguchi H, Park PMC, Wang T, Gryder BE, Ogiya D, Kurata K, Zhang X, Li D, Pei C, Masuda T, Johansson C, Wimalasena VK, Kim Y, Hino S, Usuki S, Kawano Y, Samur MK, Tai Y, Munshi NC, Matsuoka M, Ohtsuki S, Nakao M, Minami T, Lauberth S, Khan J, Oppermann U, Durbin AD, Anderson KC#, Hideshima T#, Qi J# (Lead Contact). Blood Cancer Discovery, In Press.
Development of Dimethylisoxazole-Attached Imidazo[1,2-a]pyridines as Potent and Selective CBP/P300 Inhibitors.
Muthengi A,* Wimalasena VK,* Yosief HO,* Bikowitz MJ,* Sigua LH, Wang T, Li D, Gaieb Z, Dhawan G, Liu S, Erickson J, Amaro RE, Schönbrunn E#, Qi J#, Zhang W.# J Med Chem. 2021 Apr 19. doi: 10.1021/acs.jmedchem.0c02232. Online ahead of print. PMID: 33872011
2020 Key Publications
Epigenetic CRISPR screens identify Npm1 as a therapeutic vulnerability in non-small cell lung cancer.
Li F*, Ng WL*, Luster TA, Hu H, Sviderskiy VO, Dowling CM, Hollinshead KER, Zouitine P, Zhang H, Huang Q, Ranieri M, Wang W, Fang Z, Chen T, Deng J, Zhao K, So HC, Khodadadi-Jamayran A, Xu M, Karatza A, Pyon V, Li S, Pan Y, Labbe K, Almonte C, Poirier JT, Miller G, Possemato R, Qi J#, Wong KK#.
Cancer Res. 2020 Jul 9:canres.3782.2019. doi: 10.1158/0008-5472.CAN-19-3782. Online ahead of print.
Using Chemical Epigenetics to Target Cancer.
Wimalasena VK*, Wang T*, Sigua LH*, Durbin AD#, Qi J#.
Molecular Cell. 2020 May 5. pii: S1097-2765(20)30265-3. doi: 10.1016/j.molcel.2020.04.023. [Epub ahead of print] Review.
2019 Key Publications
Chemical genomics reveals histone deacetylases are required for core regulatory transcription
Berkley E. Gryder*, Lei Wu*, Girma M. Woldemichael, Silvia Pomella, Taylor R. Quinn, Paul M. C. Park, Abigail Cleveland, Benjamin Z. Stanton, Young Song, Rossella Rota, Olaf Wiest, Marielle E. Yohe, Jack F. Shern, Jun Qi‡ & Javed Khan‡.
Nature Communications. 2019 July 08; doi: 10.1038/s41467-019-11046-7
BCL2 Amplicon loss and transcriptional remodeling drives ABT-199 resistance in B-cell lymphoma models
Zhao X*, Ren Y*, Lawlor MA*, Shah BD, Park PMC, Lwin T, Wang X, Liu K, Wang M, Gao J, Li T, Xu M, Silva AS, Lee K, Zhang T, Koomen JM, Jiang H, Sudalagunta PR, Meads MB, Cheng F, Bi C, Fu K, Fan H, Dalton WS, Moscinski LC, Shain KH, Sotomayor EM, Wang GG, Gray NS, Cleveland JL, Qi J‡, Tao J‡.
Cancer Cell. 2019 May 13;35(5):752-766.e9. doi: 10.1016/j.ccell.2019.04.005. PMID: 31085176
Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma
Song Y*, Park PMC*, Wu L, Ray A, Picaud S, Li D, Wimalasena VK, Du T, Filippakopoulos P, Anderson KC‡, Qi J‡, Chauhan D‡.
Leukemia. 2019 April 08; doi: 10.1038/s41375-019-0467-z. PMID:30962579
2018 Key Publications
YAP1-mediated suppression of USP31 enhances NFKB activity to promote sarcomagenesis
Ye S, Lawlor MA, Rivera-Reyes A, Egolf S, Chor S, Pak K, Ciotti GE, Lee AC, Marino G, Shah J, Niedzwicki D, Weber K, Park PMC, Alam MZ, Grazioli A, Haldar M, Xu M, Perry JA, Qi J‡, Eisinger-Mathason TSK‡.
Cancer Res. 2018 May 15;78(10):2705-2720. doi: 10.1158/0008-5472.CAN-17-4052. Epub 2018 Feb 28. PMID:29490948
Leukemia-specific delivery of mutant NOTCH1 targeted therapy
Roti G*, Qi J*, Kitara S, Sanchez-Martin M, Saur Conway A, Varca AC, Su A, Wu L, Ferrando AA, Brander JE, Stegmaier K.
J Exp Med. 2018 Jan 2;215(1):197-216. doi: 10.1084/jem.20151778. Epub 2017 Nov 20. PMID:29158376
* equal contribution
‡ shared corresponding authors
Full list of Qi lab publication:
https://www.ncbi.nlm.nih.gov/myncbi/jun.qi.1/bibliography/public/
Identifying regulators of aberrant stem cell and differentiation activity in colorectal cancer using a dual endogenous reporter system.
Spisak S, Chen D, Likasitwatanakul P, Doan P, Li Z, Bala P, Vizkeleti L, Tisza V, De Silva P, Giannakis M, Wolpin B, Qi J, Sethi NS. Nat Commun. 2024 Mar 12;15(1):2230. doi: 10.1038/s41467-024-46285-w.PMID: 38472198 Free PMC article.
BRD9-SMAD2/3 Orchestrates Stemness and Tumorigenesis in Pancreatic Ductal Adenocarcinoma.
Feng Y, Cai L, Pook M, Liu F, Chang CH, Mouti MA, Nibhani R, Militi S, Dunford J, Philpott M, Fan Y, Fan GC, Liu Q, Qi J, Wang C, Hong W, Morgan H, Wang M, Sadayappan S, Jegga AG, Oppermann U, Wang Y, Huang W, Jiang L, Pauklin S. Gastroenterology. 2024 Jan;166(1):139-154.
2023
A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeutics.
Lee HM, Wright WC, Pan M, Low J, Currier D, Fang J, Singh S, Nance S, Delahunty I, Kim Y, Chapple RH, Zhang Y, Liu X, Steele JA, Qi J, Pruett-Miller SM, Easton J, Chen T, Yang J, Durbin AD, Geeleher P. Nat Commun. 2023 Nov 13;14(1):7332 doi: 10.1038/s41467-023-43134-0.PMID: 37957169
Combination therapies to improve the efficacy of immunotherapy in triple-negative breast cancer.
Alečković M, Li Z, Zhou N, Qiu X, Lulseged B, Foidart P, Huang XY, Garza K, Shu S, Kesten N, Li R, Lim K, Garrido-Castro AC, Guerriero JL, Qi J, Long HW, Polyak K.Mol Cancer Ther. 2023 Sep 7. doi: 10.1158/1535-7163.MCT-23-0303. Online ahead of print.PMID: 37676980
Manipulating Tyrosine Phosphorylation by Heterobifunctional Small Molecules.
Meng X, Qi J. ACS Cent Sci. 2023 Aug 15;9(8):1512-1514. doi: 10.1021/acscentsci.3c00836. eCollection 2023 Aug 23.PMID: 37637739 Free PMC article.
Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.
de Miguel FJ, Gentile C, Feng WW, Silva SJ, Sankar A, Exposito F, Cai WL, Melnick MA, Robles-Oteiza C, Hinkley MM, Tsai JA, Hartley AV, Wei J, Wurtz A, Li F, Toki MI, Rimm DL, Homer R, Wilen CB, Xiao AZ, Qi J, Yan Q, Nguyen DX, Jänne PA, Kadoch C, Politi KA.Cancer Cell. 2023 Aug 14;41(8):1516-1534.e9. doi: 10.1016/j.ccell.2023.07.005. Epub 2023 Aug 3.PMID: 37541244 Free article.
Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1-EEF1A1 Axis.
Li M, Yang L, Chan AKN, Pokharel SP, Liu Q, Mattson N, Xu X, Chang WH, Miyashita K, Singh P, Zhang L, Li M, Wu J, Wang J, Chen B, Chan LN, Lee J, Zhang XH, Rosen ST, Müschen M, Qi J, Chen J, Hiom K, Bishop AJR, Chen CW. Adv Sci (Weinh). 2023 Jun;10(17):e2206584. doi: 10.1002/advs.202206584. Epub 2023 Apr 19.PMID: 37075745 Free PMC article.
Stepwise activities of mSWI/SNF family chromatin remodeling complexes direct T cell activation and exhaustion.
Battistello E, Hixon KA, Comstock DE, Collings CK, Chen X, Rodriguez Hernaez J, Lee S, Cervantes KS, Hinkley MM, Ntatsoulis K, Cesarano A, Hockemeyer K, Haining WN, Witkowski MT, Qi J, Tsirigos A, Perna F, Aifantis I, Kadoch C. Mol Cell. 2023 Apr 20;83(8):1216-1236.e12. doi: 10.1016/j.molcel.2023.02.026. Epub 2023 Mar 20.PMID: 36944333 Free PMC article.
Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection.
Wei J, Patil A, Collings CK, Alfajaro MM, Liang Y, Cai WL, Strine MS, Filler RB, DeWeirdt PC, Hanna RE, Menasche BL, Ökten A, Peña-Hernández MA, Klein J, McNamara A, Rosales R, McGovern BL, Luis Rodriguez M, García-Sastre A, White KM, Qin Y, Doench JG, Yan Q, Iwasaki A, Zwaka TP, Qi J, Kadoch C, Wilen CB.Nat Genet. 2023 Mar;55(3):471-483. doi: 10.1038/s41588-023-01307-z. Epub 2023 Mar 9.PMID: 36894709 Free PMC article.
BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.
Kurata K, Samur MK, Liow P, Wen K, Yamamoto L, Liu J, Morelli E, Gulla A, Tai YT, Qi J, Hideshima T, Anderson KC.Clin Cancer Res. 2023 May 1;29(9):1807-1821. doi: 10.1158/1078-0432.CCR-22-3668.PMID: 36780189 Free PMC article.
BRD9-containing non-canonical BAF complex maintains somatic cell transcriptome and acts as a barrier to human reprogramming.
Sevinç K, Sevinç GG, Cavga AD, Philpott M, Kelekçi S, Can H, Cribbs AP, Yıldız AB, Yılmaz A, Ayar ES, Arabacı DH, Dunford JE, Ata D, Sigua LH, Qi J, Oppermann U, Onder TT.Stem Cell Reports. 2022 Dec 13;17(12):2629-2642. doi: 10.1016/j.stemcr.2022.10.005. Epub 2022 Nov 3.PMID: 36332631 Free PMC article.
2022
BAF complex maintains glioma stem cells in pediatric H3K27M-glioma.
Panditharatna E, G Marques J, Wang T, Trissal MC, Liu I, Jiang L, Beck A, Groves A, Dharia NV, Li D, Hoffman SE, Kugener G, Shaw ML, Mire HM, Hack OA, Dempster JM, Lareau C, Dai L, Sigua LH, Quezada MA, Stanton AJ, Wyatt M, Kalani Z, Goodale A, Vazquez F, Piccioni F, Doench JG, Root DE, Anastas JN, Jones KL, Saur Conway A, Stopka S, Regan MS, Liang Y, Seo HS, Song K, Bashyal P, Jerome WP, Mathewson ND, Dhe-Paganon S, Suva ML, Carcaboso AM, Lavarino C, Mora J, Nguyen QD, Ligon KL, Shi Y, Agnihotri S, Agar NYR, Stegmaier K, Stiles CD, Monje M, Golub TR, Qi J#, Filbin MG# Cancer Discov. 2022 Oct 28:CD-21-1491. doi: 10.1158/2159-8290.CD-21-1491. Online ahead of print.PMID: 36305736
Aberrant Cholesterol Metabolism and Wnt/β-Catenin Signaling Coalesce via Frizzled5 in Supporting Cancer Growth.
Zheng S, Lin J, Pang Z, Zhang H, Wang Y, Ma L, Zhang H, Zhang X, Chen M, Zhang X, Zhao C, Qi J, Cao L, Wang M, He X, Sheng R. Adv Sci (Weinh). 2022 Aug 17:e2200750. doi: 10.1002/advs.202200750. Online ahead of print.
Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity.
Guan X, Cheryala N, Karim RM, Chan A, Berndt N, Qi J, Georg GI, Schönbrunn E.J Med Chem. 2022 Aug 11;65(15):10441-10458. doi: 10.1021/acs.jmedchem.2c00453. Epub 2022 Jul 22
1,4-Dihydropyridinebutyrolactone-derived ring-opened ester and amide analogs targeting BET bromodomains.
Jiang J, Zhao PL, Sigua LH, Chan A, Schönbrunn E, Qi J, Georg GI.Arch Pharm (Weinheim). 2022 Aug 8:e2200288. doi: 10.1002/ardp.202200288.
SMARCE1 deficiency generates a targetable mSWI/SNF dependency in clear cell meningioma.
St Pierre R, Collings CK, Samé Guerra DD, Widmer CJ, Bolonduro O, Mashtalir N, Sankar A, Liang Y, Bi WL, Gerkes EH, Ramesh V, Qi J, Smith MJ, Meredith DM, Kadoch C.Nat Genet. 2022 Jun;54(6):861-873. doi: 10.1038/s41588-022-01077-0. Epub 2022 Jun 9.PMID: 35681054
The FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma.
Zullow HJ, Sankar A, Ingram DR, Samé Guerra DD, D'Avino AR, Collings CK, Lazcano R, Wang WL, Liang Y, Qi J, Lazar AJ, Kadoch C.Mol Cell. 2022 Apr 4:S1097-2765(22)00257-X. doi: 10.1016/j.molcel.2022.03.019. Online ahead of print.PMID: 35390276
Exploring Methods of Targeting Histone Methyltransferases and Their Applications in Cancer Therapeutics.
Wang MY, Liow P, Guzman MIT, Qi J.ACS Chem Biol. 2022 Apr 1. doi: 10.1021/acschembio.2c00062. Online ahead of print.PMID: 35363464
BET-bromodomain and EZH2 inhibitor treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.
Zaiken MC, Flynn R, Paz KG, Rhee SY, Jin S, Mohamed FA, Saha A, Thangavelu G, Park PMC, Hemming ML, Sage PT, Sharpe AH, DuPage M, Bluestone JA, Panoskaltsis-Mortari A, Cutler CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Luznik L, Maillard I, Hill GR, MacDonald KP, Munn DH, Serody JS, Murphy WJ, Kean LS, Zhang Y, Bradner JE, Qi J#, Blazar BR#. Blood. 2022 Feb 28:blood.2021014557. doi: 10.1182/blood.2021014557. Online ahead of print.PMID: 35226736
A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia.
Ren Z, Kim A, Huang YT, Pi WC, Gong W, Yu X, Qi J, Jin J, Cai L, Roeder RG, Chen WY, Wang GG.Proc Natl Acad Sci U S A. 2022 Mar 1;119(9):e2122940119. doi: 10.1073/pnas.2122940119.PMID: 35217626
EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma.
Durbin AD*#, Wang T*, Wimalasena VK, Zimmerman MW, Li D, Dharia NV, Mariani L, Shendy NAM, Nance S, Patel AG, Shao Y, Mundada M, Maxham L, Park PMC, Sigua LH, Morita K, Saur Conway A, Robichaud AL, Perez-Atayde AR, Bikowitz MJ, Quinn TR, Wiest OG, Easton J, Schonbrunn E, Bulyk ML, Abraham BJ, Stegmaier K#, Look AT#, Qi J.# Cancer Discovery. 2021 Nov 12:candisc.0385.2021. doi: 10.1158/2159-8290.CD-21-0385. 2022, 730-751
2021 Key Publications
Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma
Ohguchi H, Park PMC, Wang T, Gryder BE, Ogiya D, Kurata K, Zhang X, Li D, Pei C, Masuda T, Johansson C, Wimalasena VK, Kim Y, Hino S, Usuki S, Kawano Y, Samur MK, Tai Y, Munshi NC, Matsuoka M, Ohtsuki S, Nakao M, Minami T, Lauberth S, Khan J, Oppermann U, Durbin AD, Anderson KC#, Hideshima T#, Qi J# (Lead Contact). Blood Cancer Discovery, In Press.
Development of Dimethylisoxazole-Attached Imidazo[1,2-a]pyridines as Potent and Selective CBP/P300 Inhibitors.
Muthengi A,* Wimalasena VK,* Yosief HO,* Bikowitz MJ,* Sigua LH, Wang T, Li D, Gaieb Z, Dhawan G, Liu S, Erickson J, Amaro RE, Schönbrunn E#, Qi J#, Zhang W.# J Med Chem. 2021 Apr 19. doi: 10.1021/acs.jmedchem.0c02232. Online ahead of print. PMID: 33872011
2020 Key Publications
Epigenetic CRISPR screens identify Npm1 as a therapeutic vulnerability in non-small cell lung cancer.
Li F*, Ng WL*, Luster TA, Hu H, Sviderskiy VO, Dowling CM, Hollinshead KER, Zouitine P, Zhang H, Huang Q, Ranieri M, Wang W, Fang Z, Chen T, Deng J, Zhao K, So HC, Khodadadi-Jamayran A, Xu M, Karatza A, Pyon V, Li S, Pan Y, Labbe K, Almonte C, Poirier JT, Miller G, Possemato R, Qi J#, Wong KK#.
Cancer Res. 2020 Jul 9:canres.3782.2019. doi: 10.1158/0008-5472.CAN-19-3782. Online ahead of print.
Using Chemical Epigenetics to Target Cancer.
Wimalasena VK*, Wang T*, Sigua LH*, Durbin AD#, Qi J#.
Molecular Cell. 2020 May 5. pii: S1097-2765(20)30265-3. doi: 10.1016/j.molcel.2020.04.023. [Epub ahead of print] Review.
2019 Key Publications
Chemical genomics reveals histone deacetylases are required for core regulatory transcription
Berkley E. Gryder*, Lei Wu*, Girma M. Woldemichael, Silvia Pomella, Taylor R. Quinn, Paul M. C. Park, Abigail Cleveland, Benjamin Z. Stanton, Young Song, Rossella Rota, Olaf Wiest, Marielle E. Yohe, Jack F. Shern, Jun Qi‡ & Javed Khan‡.
Nature Communications. 2019 July 08; doi: 10.1038/s41467-019-11046-7
BCL2 Amplicon loss and transcriptional remodeling drives ABT-199 resistance in B-cell lymphoma models
Zhao X*, Ren Y*, Lawlor MA*, Shah BD, Park PMC, Lwin T, Wang X, Liu K, Wang M, Gao J, Li T, Xu M, Silva AS, Lee K, Zhang T, Koomen JM, Jiang H, Sudalagunta PR, Meads MB, Cheng F, Bi C, Fu K, Fan H, Dalton WS, Moscinski LC, Shain KH, Sotomayor EM, Wang GG, Gray NS, Cleveland JL, Qi J‡, Tao J‡.
Cancer Cell. 2019 May 13;35(5):752-766.e9. doi: 10.1016/j.ccell.2019.04.005. PMID: 31085176
Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma
Song Y*, Park PMC*, Wu L, Ray A, Picaud S, Li D, Wimalasena VK, Du T, Filippakopoulos P, Anderson KC‡, Qi J‡, Chauhan D‡.
Leukemia. 2019 April 08; doi: 10.1038/s41375-019-0467-z. PMID:30962579
2018 Key Publications
YAP1-mediated suppression of USP31 enhances NFKB activity to promote sarcomagenesis
Ye S, Lawlor MA, Rivera-Reyes A, Egolf S, Chor S, Pak K, Ciotti GE, Lee AC, Marino G, Shah J, Niedzwicki D, Weber K, Park PMC, Alam MZ, Grazioli A, Haldar M, Xu M, Perry JA, Qi J‡, Eisinger-Mathason TSK‡.
Cancer Res. 2018 May 15;78(10):2705-2720. doi: 10.1158/0008-5472.CAN-17-4052. Epub 2018 Feb 28. PMID:29490948
Leukemia-specific delivery of mutant NOTCH1 targeted therapy
Roti G*, Qi J*, Kitara S, Sanchez-Martin M, Saur Conway A, Varca AC, Su A, Wu L, Ferrando AA, Brander JE, Stegmaier K.
J Exp Med. 2018 Jan 2;215(1):197-216. doi: 10.1084/jem.20151778. Epub 2017 Nov 20. PMID:29158376
* equal contribution
‡ shared corresponding authors
Full list of Qi lab publication:
https://www.ncbi.nlm.nih.gov/myncbi/jun.qi.1/bibliography/public/